Related Experiment Video

Updated: Jul 17, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

[Prevention of atrial fibrillation in hypertensive patients]

Vivencio Barrios Alonso1, Mariano de la Figuera von Wichmann, Antonio Coca Payeras

  • 1Instituto de Cardiología, Hospital Ramón y Cajal. Madrid, España. vbarriosa@meditex.es

Medicina Clinica
|February 10, 2007
PubMed

Insights

Hypertension and atrial fibrillation (AF) often coexist. Inhibiting the renin-angiotensin-aldosterone system with ACE inhibitors or ARBs shows promise in preventing AF in hypertensive patients, though more trials are needed.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Research

Context:

  • Hypertension is a significant risk factor for atrial fibrillation (AF), creating a detrimental cycle.
  • Atrial fibrillation exacerbates hypertension, complicating patient management.
  • Targeting specific signal transduction pathways offers a promising therapeutic strategy for AF in hypertensive individuals.

Purpose:

  • To review the effectiveness of renin-angiotensin-aldosterone system (RAAS) inhibitors in preventing atrial fibrillation (AF) in patients with hypertension.
  • To assess the role of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs) in managing the interplay between hypertension and AF.

Summary:

  • Inhibition of the RAAS, particularly with ACEIs and ARBs, is a key mechanism being investigated for AF prevention in hypertensive patients.
  • Clinical trials suggest that both ACEIs and ARBs are effective in preventing AF.
  • However, the current evidence base, limited by a lack of prospective randomized double-blind trials, restricts their widespread application solely for AF prevention.

Impact:

  • Provides insight into the therapeutic potential of RAAS inhibitors for AF prevention in hypertensive populations.
  • Highlights the need for further rigorous clinical trials to solidify the role of ACEIs and ARBs in this specific indication.
  • Informs clinical practice regarding the current limitations and future research directions for managing comorbid hypertension and AF.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.